Navigating the new Medicare drug benefit

Area of Science:

• Health Policy
• Pharmaceutical Benefits
• Medicare Reform

Background:

• Medicare beneficiaries have awaited an outpatient prescription drug benefit for 40 years.
• The Medicare Prescription Drug, Improvement and Modernization Act of 2003 was enacted to provide drug coverage.
• This legislation aims to offer at least limited drug coverage to all eligible Medicare beneficiaries.

Purpose of the Study:

• To provide a fundamental understanding of the new Medicare drug benefit's mechanics.
• To analyze the factors influencing the structure and design of the new drug benefit.
• To examine the implications of the Medicare Prescription Drug, Improvement and Modernization Act of 2003.

Main Methods:

• Commentary and analysis of the Medicare Prescription Drug, Improvement and Modernization Act of 2003.
• Review of legislative intent and potential impact on beneficiaries.
• Examination of the benefit's structure compared to existing Medicare provisions.

Main Results:

• The new drug benefit was shaped by ideology and spending constraints.
• The benefit package is generous for low-income beneficiaries with limited assets but has coverage gaps for others.
• Beneficiaries will choose from private stand-alone drug plans, managed care organizations, or employer-sponsored plans after a transitional discount card program.

Conclusions:

• The benefit's structure represents a significant departure from traditional Medicare provisions.
• Key questions remain regarding the enrollment of private drug plans, employer-sponsored coverage, impact on Medicare managed care, and beneficiary comprehension.
• The success of Medicare drug coverage hinges on resolving these critical issues and beneficiary response.